Argenta Limited

Pharmacy Market

AIkido Pharma Inc. | March 04, 2022

AIkido Pharma Inc.reported an improvement in the manufacturing process for its pancreatic cancer drug, DHA-dFdC, licensed from the University of Texas at Austin. The Company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug. With respect to manufacturing process, the Company reported the successful development of a new means for the scaled pro...

Fool.com | January 30, 2020

The premise of generic drugs was simple enough. Branded medicines protected by a patent tend to be overpriced, but the equivalent therapy made by other companies once a patent expires should lead to price-lowering competition. As it turns out, however, generic drugs have become overpriced as well. That's the stance the state of California has taken, anyway, with Governor Gavin Newsom announcing early this month the state is planning to launch its own prescription drug label. The Blue Cross B...

Technology Networks | February 17, 2020

Arctoris Ltd has announced a formal partnership with Molecule in order to tackle the ongoing innovation crisis faced by drug discovery and development across both industry and academia. Through its fully automated drug discovery platform, Arctoris aims to enable researchers and biotechnological entrepreneurs to design and remotely execute advanced cell-based, molecular biology and biochemical assays. Together with Molecule’s distributed IP ownership platform, which enables stakeholders in ...

Labiotech.eu | February 21, 2020

The German biotech Immatics will partner with GSK and could receive more than €1B from the big pharma for developing cancer immunotherapies based on engineered immune T-cells. Immatics will collaborate with GSK to develop two T-cell therapies that express a protein engineered to detect cancer antigens and kill cancer cells. In return, Immatics will receive €46M upfront and €509M in undisclosed developmental and commercial milestone payments per program, plus royalties. These thera...